{"nctId":"NCT04546581","briefTitle":"Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)","startDateStruct":{"date":"2020-10-08","type":"ACTUAL"},"conditions":["COVID","COVID-19","SARS-CoV-2","SARS (Severe Acute Respiratory Syndrome)"],"count":593,"armGroups":[{"label":"Intervention Group","type":"EXPERIMENTAL","interventionNames":["Biological: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)","Drug: Remdesivir"]},{"label":"Control Group","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo","Drug: Remdesivir"]}],"interventions":[{"name":"Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Remdesivir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* SARS-CoV-2 infection documented by polymerase chain reaction (PCR) or other nucleic acid test (NAT) within 3 days prior to randomization OR documented by NAT more than 3 days prior to randomization AND progressive disease suggestive of ongoing SARS-CoV-2 infection\n* Symptomatic COVID-19 disease\n* Duration of symptoms attributable to COVID-19 â‰¤ 12 days\n* Requiring inpatient hospital medical care for clinical manifestations of COVID-19 (admission for public health or quarantine only is not included)\n* Willingness to abstain from participation in other COVID-19 treatment trials until after study Day 7\n* Provision of informed consent by participant or legally authorized representative\n\nExclusion Criteria:\n\n* Prior receipt of SARS-CoV-2 hIVIG or convalescent plasma from a person who recovered from COVID-19 at any time\n* Prior receipt of standard IVIG (not hyperimmune to SARS-CoV-2) within 45 days\n* Current or predicted imminent (within 24 hours) requirement for any of the following:\n\n  1. Invasive ventilation\n  2. Non-invasive ventilation\n  3. Extracorporeal membrane oxygenation\n  4. Mechanical circulatory support\n  5. Continuous vasopressor therapy\n* History of allergy to IVIG or plasma products\n* History of selective IgA deficiency with documented presence of anti-IgA antibodies\n* Any medical conditions for which receipt of the required volume of intravenous fluid may be dangerous to the patient (includes New York Association Class III or IV stage heart failure)\n* Any of the following thrombotic or procoagulant disorders:\n\n  1. Acute coronary syndromes, cerebrovascular syndromes and pulmonary or deep venous thrombosis within 28 days of randomization\n  2. History of prothrombin gene mutation 20210, homozygous Factor V Leiden mutations, antithrombin III deficiency, protein C deficiency, protein S deficiency or antiphospholipid syndrome\n* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject or that could prevent, limit, or confound the protocol-specified assessments","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ordinal Outcome Scale - Day 7","description":"The primary objective is to compare the clinical status of patients in each group on day 7 of follow-up using the primary ordinal outcome with 7 mutually exclusive categories:\n\n7\\. Death 6. End-organ failure 5. Life-threatening end-organ dysfunction 4. Serious end-organ dysfunction 3. Moderate end-organ dysfunction 2. Limiting symptoms due to COVID-19\n\n1\\. No limiting symptoms due to COVID-19\n\nOutcome is reported as the percent of participants in each of 7 categories. Primary ordinal outcome based on the patient's clinical status on Day 7. It includes 7 mutually exclusive categories capturing the range of organ dysfunction that may be associated with progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.\n\nMinimum value = 1, Maximum value = 7 Higher scores mean a worse outcome","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Primary Safety Outcome - Death, SAE or Grade 3 or 4 Events Through Day 7","description":"Number of participants with death, SAE or Grade 3 or 4 event through Day 7","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"N Reaching 3 Least Favorable Categories","description":"N Reaching 3 least favorable categories of ordinal outcome (Categories 5, 6, 7: life-threatening end organ dysfunction, end organ failure, or death)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"N Reaching 2 Most Favorable Categories","description":"N Reaching 2 most favorable categories of ordinal outcome (Categories 1 and 2: not requiring oxygen with or without limiting symptoms due to COVID-19)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"160","spread":null}]}]}]},{"type":"SECONDARY","title":"N Discharged or in Most Favorable Category","description":"N discharged from hospital or reaching most favorable ordinal category (category 1: not requiring oxygen and no limiting symptoms due to COVID-19)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"268","spread":null},{"groupId":"OG001","value":"252","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":301},"commonTop":["Dyspnoea","Pyrexia","Respiratory Distress","Chills","Respiratory Failure"]}}}